APA (7th ed.) Citation

Charles‐Schoeman, C., Fleischmann, R., Mysler, E., Greenwald, M., Ytterberg, S. R., Koch, G. G., . . . Szekanecz, Z. (2024). Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients. Arthritis & rheumatology (Hoboken, N.J.), 76(8), 1218-1229. https://doi.org/10.1002/art.42846

Chicago Style (17th ed.) Citation

Charles‐Schoeman, Christina, et al. "Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients." Arthritis & Rheumatology (Hoboken, N.J.) 76, no. 8 (2024): 1218-1229. https://doi.org/10.1002/art.42846.

MLA (9th ed.) Citation

Charles‐Schoeman, Christina, et al. "Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients." Arthritis & Rheumatology (Hoboken, N.J.), vol. 76, no. 8, 2024, pp. 1218-1229, https://doi.org/10.1002/art.42846.